NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
06/26/2026
Back to search
Official data from USPTO
TRANSCELERATE BIOPHARMA INC.
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
07/21/2026
Trademark type
Combined
Nice classes
35, 41, 42
Filing date
09/04/2015
Registration date
08/30/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/26/2026
Last transaction
07/21/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
2013-01-00
First use in commerce
2013-01-00
Drawing code
3
Owner type
03
Owner location
West Conshohocken, PA, US
Examiner
WILKE, JOHN
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of three nested angle bracket symbols to the left of the words "TransCelerate" with the words "BIOPHARMA INC." in capital letters underneath.
Holders and representatives
Holders
TransCelerate BioPharma Inc.
Representatives
Jason M. Vogel Kilpatrick Townsend & Stockton Llp
Technical classification
Nice Classes
Class 35Class 41Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Trade association servicespromoting the interests of the pharmaceutical and biotechnological industries
Class 41
Educational servicesproviding classesworkshopsseminars and educational exhibitions and fairs in the field of clinical trials and pharmaceuticals; providing clinical research education to healthcare professionals
Class 42
Providing a website featuring information in the field of clinical research and clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Publications
History of USPTO decisions and trademark events.
34 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
06/26/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
06/26/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/26/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
04/23/2026
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
08/30/2025
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
01/17/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
01/17/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/14/2023
E815
TEAS SECTION 8 & 15 RECEIVED
06/29/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
08/30/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
08/30/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/14/2016
PUBO
PUBLISHED FOR OPPOSITION
06/14/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/25/2016
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/23/2016
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/23/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/11/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/02/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/30/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/30/2016
ALIE
ASSIGNED TO LIE
04/27/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/12/2016
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
12/17/2015
GPRA
PRIORITY ACTION E-MAILED
12/17/2015
CPRA
PRIORITY ACTION WRITTEN
12/17/2015
XAEC
EXAMINER'S AMENDMENT ENTERED
12/17/2015
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/17/2015
GNEA
EXAMINERS AMENDMENT E-MAILED
12/17/2015
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/17/2015
DOCK
ASSIGNED TO EXAMINER
12/17/2015
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/10/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2015
NWAP
NEW APPLICATION ENTERED
09/08/2015
Continuous trademark protection
Get notified about every new filing that threatens TRANSCELERATE BIOPHARMA INC. or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.